Amplifi Vascular Launches AMPLIFI-1 Pivotal Trial for Hemodialysis Access Innovation
Amplifi Vascular has launched the AMPLIFI-1 pivotal trial to evaluate the effectiveness of its Vein Dilation System in creating arteriovenous fistulas (AVFs) for hemodialysis access. The trial aims to determine if the therapy can enable AVF maturation in just two weeks, thereby reducing catheter dependence and improving patient outcomes. Early results from Brigham and Women’s Hospital show promising signs of AVF maturation, which could transform dialysis access practices.
Study evaluates whether Amplifi therapy enables AVF maturation at two weeks, potentially reducing catheter dependence and transforming the dialysis access pathway BOSTON, May 19, 2026 /PRNewswire/ — Amplifi Vascular, a clinical-stage medical technology company developing the Amplifi™…